Table 3.
Multivariate analyses of the predictors for mortality during treatment including combination therapy, carbapenems or colistin use, and polymicrobial pneumonia
| Variables | Odds ratio | 95 % confidence interval | p |
|---|---|---|---|
| Model Aa | |||
| With skin and soft tissue infection | 2.041 | 0.644–6.466 | 0.225 |
| MDR Acb complex with TG or SB resistance | 0.418 | 0.160–1.092 | 0.075 |
| Bilateral pneumonia | 2.663 | 0.987–7.186 | 0.053 |
| Tigecycline-based treatment | 1.405 | 0.608–3.245 | 0.426 |
| Combination therapy | 1.133 | 0.472–2.720 | 0.779 |
| Model Bb | |||
| With skin and soft tissue infection | 2.071 | 0.657–6.523 | 0.214 |
| MDR Acb complex with TG or SB resistance | 0.426 | 0.163–1.114 | 0.082 |
| Bilateral pneumonia | 2.717 | 1.007–7.329 | 0.048 |
| Tigecycline-based treatment | 1.373 | 0.497–3.795 | 0.541 |
| Combination with carbapenem | 1.002 | 0.346–2.905 | 0.997 |
| Model Cc | |||
| With skin and soft tissue infection | 2.002 | 0.624–6.425 | 0.243 |
| MDR Acb complex with TG or SB resistance | 0.420 | 0.161–1.090 | 0.075 |
| Bilateral pneumonia | 2.795 | 1.028–7.600 | 0.044 |
| Tigecycline-based treatment | 1.430 | 0.608–3.363 | 0.413 |
| Combination with colistin | 0.783 | 0.178–3.444 | 0.746 |
| Model D | |||
| With skin and soft tissue infection | 2.035 | 0.639–6.485 | 0.230 |
| MDR Acb complex with TG or SB resistance | 0.428 | 0.165–1.111 | 0.081 |
| Bilateral pneumonia | 2.711 | 1.013–7.254 | 0.047 |
| Tigecycline-based treatment | 1.362 | 0.598–3.102 | 0.462 |
| Polymicrobial pneumonia | 1.109 | 0.426–2.884 | 0.833 |
| Model E | |||
| With skin and soft tissue infection | 1.979 | 0.612–6.405 | 0.254 |
| MDR Acb complex with TG or SB resistance | 0.422 | 0.160–1.110 | 0.080 |
| Bilateral pneumonia | 2.781 | 1.014–7.624 | 0.047 |
| Tigecycline-based treatment | 1.422 | 0.498–4.056 | 0.510 |
| Polymicrobial pneumonia | 1.086 | 0.413–2.853 | 0.868 |
| Combination with colistin | 0.797 | 0.179–3.557 | 0.767 |
| Combination with carbapenem | 1.006 | 0.346–2.921 | 0.991 |
Abbreviations: MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii, TG tigecycline, SB sulbactam
aNo significant predictor was revealed when model A included polymicrobial pneumonia
bBilateral pneumonia was the only significant predictor when model B included polymicrobial pneumonia (p = 0.049, adjusted odds ratio, 2.709; 95 % confidential interval, 1.004–7.305)
cBilateral pneumonia was the only significant predictor when model C included polymicrobial pneumonia (p = 0.045, adjusted odds ratio, 2.783; 95 % confidential interval, 1.023–7.569)